BRCA1 and breast cancer: For example, the current United Kingdom NICE guidelines recommend enhanced surveillance for women with a lifetime risk greater than 17% of developing breast cancer, regardless of their BRCA1/2 status.40 Similar approaches may be developed for male carriers of BRCA1/2 mutations for whom management would differ on the basis of their individual lifetime risk.